Lymphotropic nanoparticle-enhanced MRI in prostate cancer: value and therapeutic potential.
about
Prostate MRI - an update for the referring urologistA comprehensive literatures update of clinical researches of superparamagnetic resonance iron oxide nanoparticles for magnetic resonance imaging.Imaging biomarkers in prostate cancer: role of PET/CT and MRI.Emerging Role of MRI for Radiation Treatment Planning in Lung Cancer.Ultra-small superparamagnetic iron oxides for metastatic lymph node detection: back on the block.Computer-aided Detection of Prostate Cancer with MRI: Technology and Applications.Percutaneous MR-guided focal cryoablation for recurrent prostate cancer following radiation therapy: retrospective analysis of iceball margins and outcomesImaging of local recurrence in prostate cancer.Magnetic nanoformulations for prostate cancer.Automated multistructure atlas-assisted detection of lymph nodes using pelvic MR lymphography in prostate cancer patients.Ferumoxytol as an intraprostatic MR contrast agent for lymph node mapping of the prostate: a feasibility study in non-human primates.A novel method for intraoperative sentinel lymph node detection in prostate cancer patients using superparamagnetic iron oxide nanoparticles and a handheld magnetometer: the initial clinical experience.Multiparametric characterization of response to anti-angiogenic therapy using USPIO contrast-enhanced MRI in combination with dynamic contrast-enhanced MRI.Reconsidering the role of pelvic lymph node dissection with radical prostatectomy for prostate cancer in an era of improving radiological staging techniques.Prostate cancer post-treatment follow-up and recurrence evaluation.Ultra-small superparamagnetic iron oxide contrast agents for lymph node staging of high-risk prostate cancer
P2860
Q26739725-35BF010D-0C3D-439B-B91F-A9D05FD3F7BFQ36301599-026DFF35-974C-4697-A5A4-286EF3EEDD3DQ38321182-458F75E3-7D81-4D12-866F-2A06CF138276Q38641099-859B5E5F-EA89-4A6E-9EB1-69C2EF823988Q38734277-35FA1F38-2F62-4F05-BD1E-1CA09D2208BEQ38822172-B735C026-63CB-4DB5-AFD3-D2FA81F2367CQ38837262-D728777D-A9C1-44EC-800A-CDE161457385Q38852724-EA0D2C04-D577-4218-B35E-DA65E24FDD44Q39319113-6001AFAA-C3AB-438F-AF04-2A7E142F9CC4Q39700070-4C88B7BA-24B1-43C0-BCEA-4258DBC2DA4BQ41715990-AB56B307-C483-4A6F-AC9D-62AC7BB7199AQ42973879-AD8B6A6E-1A6A-4DDD-8063-6C4DD185B6F2Q47367815-4AACC72C-B77B-4389-ACDB-19B83F52004EQ48342936-C82C247B-A9B7-427F-850A-2056E39B4B33Q52982867-7E21AF79-AD33-49F8-A6D7-4EB1AE165DFCQ58562134-E5803C70-88F3-4D8C-BE22-28434A2F5C8A
P2860
Lymphotropic nanoparticle-enhanced MRI in prostate cancer: value and therapeutic potential.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Lymphotropic nanoparticle-enha ...... lue and therapeutic potential.
@en
type
label
Lymphotropic nanoparticle-enha ...... lue and therapeutic potential.
@en
prefLabel
Lymphotropic nanoparticle-enha ...... lue and therapeutic potential.
@en
P2093
P2860
P1476
Lymphotropic nanoparticle-enha ...... lue and therapeutic potential.
@en
P2093
Alfred J Witjes
Ansje S Fortuin
Hanneke J M Meijer
Jelle O Barentsz
Robert Jan Smeenk
P2860
P2888
P356
10.1007/S11934-013-0389-7
P577
2014-03-01T00:00:00Z
P5875
P6179
1048654305